Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coiled-coil domain-containing protein 150 (CCDC150)
- Target
- CCDC150
- Molecular classification
- Other (Coiled-coil domain-containing protein), Cytoskeleton-associated protein
01
Overview
Coiled-coil domain-containing protein 150 (CCDC150) is a member of the CCDC family, proteins that contain multiple coiled-coil domains crucial for cytoskeleton assembly and actin polymerization[2][3][4]. CCDC150 is upregulated in triple-negative breast cancer (TNBC), where high expression correlates with metastasis and poor patient survival[2]. It participates in cellular organization and cytoskeletal rearrangement, influencing cell motility and invasion. Knockdown of CCDC150 in cancer cell lines reduces invasion and tumor growth, underscoring its oncogenic potential and appeal as a therapeutic target[2]. While its molecular mechanisms remain to be fully clarified, CCDC150 is also implicated in cellular stress responses[4]. Currently, there are no known drugs that specifically target CCDC150, and its safety profile in therapeutic contexts is uncharacterized. Additional studies are needed to thoroughly define its protein interactions, regulatory networks, and potential for direct pharmacological targeting.
- Other names
- CCDC150FLJ39660coiled-coil domain containing 150coiled-coil domain-containing protein 150
02
Mechanism of action
No drugs targeting CCDC150 have been reported; mechanism would depend on modality, e.g., inhibition of cytoskeletal organization.
03
Biological functions
Cytoskeleton assemblyActin polymerizationCellular component organizationCellular stress adaptation (possible)
04
Disease associations
Cancer (particularly triple-negative breast cancer; correlated with tumor progression and poor prognosis[2])Other (potential role in cellular stress response[4])
05
Safety considerations
No specific safety concerns have been reported; however, as a cytoskeleton regulator, inhibition could impact cell viability and tissue homeostasis.
06
Biomarkers
Upregulated CCDC150 expression in triple-negative breast cancer is associated with poor prognosis, suggesting possible use as a prognostic or predictive biomarker[2].
Beyond the preview
Go deeper on Coiled-coil domain-containing protein 150 (CCDC150).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coiled-coil domain-containing protein 150 (CCDC150).